title: Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery.
abstract: BACKGROUND
  Studies have revealed that stem cells improve clinical outcomes in patients with severe ischemic cardiomyopathy, but the role of bone marrow mesenchymal stem cells is not well understood.
  
  
  METHODS
  Twenty-two patients received an implantation of autologous bone marrow mesenchymal stem cell therapy; another 23 patients were placed in a control group after percutaneous coronary intervention (PCI) of the chronically occluded left anterior descending artery.
  
  
  RESULTS
  Reversible defect in the cell therapy group decreased from 16 +/- 8% at baseline to 6 +/- 2% at 12 months (p < 0.05), and this improvement was maintained throughout the entire follow-up period. Compared to the control group (5 +/- 3 METS at baseline vs. 5 +/- 3 METS at 3 months; p = NS), the level of exercise tolerance improved significantly 3 months after cell therapy (5 +/- 2 METS at baseline vs. 7 +/- 3 METS at 3 months; p < 0.05). The NYHA function class also improved in the cell therapy group (2.7 +/- 0.8 at baseline vs. 1.6 +/- 0.1 at 3 months; p < 0.05). PCI alone did not increase left ventricular ejection fraction (LVEF), but following stem cell therapy, the LVEF increased significantly from 26 +/- 6% at baseline to 37 +/- 9% at 3 months (p < 0.05).
  
  
  CONCLUSIONS
  Intracoronary transplantation of autologous bone marrow mesenchymal stem cells improved clinical outcomes in patients with chronic ischemic cardiomyopathy.
authors.affiliation: Nanjing First Hospital of Nanjing Medical University, Nanjing, China.
authors.forename: Shaoliang
authors.initials: S
authors.lastname: Chen
authors.forename: Zhizhong
authors.initials: Z
authors.lastname: Liu
authors.forename: Nailiang
authors.initials: N
authors.lastname: Tian
authors.forename: Junjie
authors.initials: J
authors.lastname: Zhang
authors.forename: Fei
authors.initials: F
authors.lastname: Yei
authors.forename: Baoxian
authors.initials: B
authors.lastname: Duan
authors.forename: Zhongsheng
authors.initials: Z
authors.lastname: Zhu
authors.forename: Song
authors.initials: S
authors.lastname: Lin
authors.forename: Tak W
authors.initials: TW
authors.lastname: Kwan
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D016026:Bone Marrow Transplantation / Q000379:methods; D009202:Cardiomyopathies / Q000209:etiology / Q000401:mortality / Q000628:therapy; D002908:Chronic Disease; D003131:Combined Modality Therapy; D017023:Coronary Angiography; D023921:Coronary Stenosis / Q000150:complications* / Q000000981:diagnostic imaging; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods*; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D011446:Prospective Studies; D012016:Reference Values; D018570:Risk Assessment; D012720:Severity of Illness Index; D015996:Survival Rate; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D014654:Vascular Patency